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Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease
Bayry Jagadeesh
To test our hypothesis, we analyzed Treg in paired blood samples of autoimmune rheumatic patients before and 72 96 hr after -high-dose IVIg therapy (Tegeline , 2g/kg per month) . The patients broadly belonged to two groups: idiopathic inflammatory myopathy
(8 patients with age ranging from 22 to 57 yr; 3 male patients) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (3 patients with age ranging from 61 to 68 yr; 2 males). The patients details are provided in . The local ethical committee approval ' Table 1 was obtained for collecting the blood samples and informed consent was taken from the patients. Peripheral blood mononuclear cells were isolated from the blood samples by ficoll-density gradient and CD4 CD25 T cells were analyzed by flow cytometry by using anti-inflammatory effects IVIg therapy is associated with enhancement of Tregs in autoimmune patients and these Tregs might further help to restore immune tolerance.
Although several immunosuppressive drugs including steroids can enhance Tregs , IVIg has an added advantage wherein this [7 ] therapy is not an immunosuppressor rather an immunomodulator. Hence adverse effects associated with immunosuppressive therapies can be avoided by IVIg therapy. [10 ]
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